A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

The U.S. Food and Drug Administration (FDA) recently approved ... Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has ... knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe sleep ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment ... Regulators can expand approval for medicines if new data shows them to be effective in other therapeutic ...

The long quest for powerful non-opioid drugs that treat pain without risk of addiction is nearing a milestone, in the form of a pill that could soon win approval from the Food and Drug Administration.

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.